Skip to main content

Cantor Fitzgerald Reaffirms Their Buy Rating on BioMarin Pharmaceutical (BMRN)

Tipranks - Tipranks - Wed Feb 25, 7:33AM CST

In a report released yesterday, Olivia Brayer from Cantor Fitzgerald maintained a Buy rating on BioMarin Pharmaceutical, with a price target of $85.00. The company’s shares closed yesterday at $62.92.

Claim 50% Off TipRanks Premium

Brayer covers the Healthcare sector, focusing on stocks such as Vanda, Insmed, and BioMarin Pharmaceutical. According to TipRanks, Brayer has an average return of 4.6% and a 46.97% success rate on recommended stocks.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BioMarin Pharmaceutical with a $86.20 average price target, a 37.00% upside from current levels. In a report released today, TD Cowen also maintained a Buy rating on the stock with a $120.00 price target.

See today’s best-performing stocks on TipRanks >>

Based on BioMarin Pharmaceutical’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $776.13 million and a GAAP net loss of $30.74 million. In comparison, last year the company earned a revenue of $745.74 million and had a net profit of $106.08 million

Read More on BMRN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).